Mutating HIV Virus Making It Difficult To Develop Vaccine

THE ever-changing genetic makeup and rapid mutation of the HIV virus has to a larger extent slowed down progress towards successfully developing an effective HIV vaccine, a top Zimbabwean expert has said. By Michael Gwarisa The revelations also follow the recent abandonment of the Imbokodo HIV vaccine or HVTN 705/HPX2008 efficacy studies after revelations that the vaccine was not granting enough protection against infection. In an interview with HealthTimes, Dr Portia Hunidzarira, the Principal Researcher for the Imbokodo vaccine studies said the HIV virus mutates at a faster rate and…

Read More

Imbokodo HIV Vaccine Study Was A Learning Phase

Dr Portia Hunidzarira, the Imbokodo Principal Researcher said the discontinuation of the HVTN 705/HPX2008 or Imbokodo study gave researchers and scientist a new platform to learn and develop evidence  for future studies that might lead to an HIV vaccine breakthrough. By Patricia Mashiri She said the vaccine proved to be safe and caused no harm to participants even though it was unable to provide sufficient protection to prevent HIV infection which the study was looking. The study which commenced in 2017 and concluded vaccinations in June 2020 wanted to test…

Read More

Oxford, Wits Universities Conducting ÇOVID-19 Vaccine Trails

Dr Portia Hunidzarira, University of Zimbabwe, Clinical Health Science (CHS)-Clinical Trials Research Centre (CTRC) in March walked journalists on the vaccine roadmap.

THE Oxford University is running COVID-19 Vaccine Clinical Trials in collaboration with Wits University of South Africa. The vaccine was developed at the University of Oxford’s Oxford Jenner Institute and is currently on trial in the UK. Over 4 000 participants are already enrolled into the clinical trial and enrolment of an additional 10 000 participants is planned. The clinical trials are running in the UK, Brazil and South Africa. Why South Africa for vaccine trials? South Africa is the epicentre of COVID-19 in Africa. With 60% of the infections…

Read More